A Prospective Natural History Study in Uveal Melanoma (NCT04588662)
🩺 Plain-English Summary (8th-Grade Level)
The overall objective of this proposal is to develop and utilize a multicenter UM registry that will, in a longitudinal fashion, capture prospective data in order to characterize the natural history of UM and provide data that will be used to support the development of novel therapies for this disease. The care of patients with UM requires a multi-disciplinary team of physicians that commonly requires the involvement of both radiation oncology and interventional radiology, and is typically directed by an ophthalmologic oncologist at time of initial diagnosis of primary disease. Overall management is transitioned to a medical oncologist when distant recurrence is identified. In the case that a patient presents with metastasis at the time of diagnosis, a medical oncologist typically directs overall management. The management of surveillance for the development of metastasis following the treatment of primary disease is variable and, if performed at all, is managed by either an ophthalmologic oncologist or medical oncologist. Thus, the successful development of a registry that aims to capture the data regarding the full natural history of UM requires a collaborative effort including leaders from both the UM ophthalmologic oncology and medical oncology fields. To this end, the investigators have built an initial consortium of key ophthalmologic oncology and medical oncology leaders from multiple major UM centers in the United States.
Who can join: Review the eligibility criteria below.
Location: Massachusetts General Hospital — Boston, Massachusetts
Age range: 18 Years
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (17 Sites)
- Massachusetts General Hospital — Boston, Massachusetts
- Memorial Sloan Kettering Cancer Center — New York, New York
- Thomas Jefferson University Hospital — Philadelphia, Pennsylvania
- MD Anderson Cancer Center — Houston, Texas
- Royal Adelaide Hospital — Adelaide,
- Chatswood Eye Specialists — Chatswood,
- Royal Victorian Eve and Ear Hospital — East Melbourne,
- Western Eye Specialists — Maribyrnong,
- Pennington Eye Clinic — North Adelaide,
- Perth Retina — Subiaco,
- Dr. Conway Private Rooms — Sydney,
- St. Vincent's Hospital — Sydney,
- Princess Margaret Cancer Center — Toronto,
- Erlangen — Erlangen,
- Clatterbridge Cancer Centre — Birkenhead,
- Mount Vernon Cancer Centre — Northwood,
- Sheffield — Sheffield,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Uveal Melanoma
- (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma — Scottsdale, Arizona
- Targeted Alpha Particle Radiotherapy for Metastatic Uveal Melanoma — Tampa, Florida
- Psychoeducation for Uveal Melanoma — Los Angeles, California
- Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma — Tampa, Florida
- Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome — Columbus, Ohio
Explore by condition: All Uveal Melanoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.